Physician profile
Ryan P Cloos
NPI 1649419672
$1,279.20
in general payments reported to CMS, 2019-2025
13 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.53 · 2020: $251 · 2021: $115 · 2022: $88.04 · 2023: $246 · 2024: $155 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $377.32 | 2023-2025 | Gamma, Variax, Alphavent |
| Depuy Synthes Sales INC. | $365.79 | 2019-2025 | Velys, Attune, Na |
| Endo Pharmaceuticals INC. | $137.03 | 2020-2022 | |
| Smith+Nephew, INC. | $102.45 | 2019-2022 | |
| Wardlow Enterprises | $90.96 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $68.44 | 2025 | |
| Sanofi-Aventis U.S. LLC | $30.92 | 2019 | |
| Ferring Pharmaceuticals INC. | $27.37 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $22.49 | 2024 | Iovera, Zilretta, Exparel |
| Merck Sharp & Dohme LLC | $16.99 | 2025 | Bridion |
| Nuvasive, INC. | $14.18 | 2019 | |
| Sanara Medtech INC. | $14.08 | 2023 | Celleraterx |
| Bioventus LLC | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cloos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.